Case Studies

Case Studies

Discovery & Development of Xanamem

Pioneering research over a number of years at the Centre for Cardiovascular revealed the enzyme 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) as a therapeutic target for the potential treatment of cardiometabolic disease and memory impairments. This research catalysed considerable efforts by the pharmaceutical industry to develop new anti-diabetic therapies culminating in the discovery of agents such as AMG-221 and BI-135585.